Tyrosine Kinase Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
| Line 38: | Line 38: | ||
! 59 | ! 59 | ||
! Variable | ! Variable | ||
| - | ! | + | ! 98 |
|- | |- | ||
! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%) | ! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%) | ||
| Line 46: | Line 46: | ||
! 90 | ! 90 | ||
! 99 | ! 99 | ||
| - | ! | + | ! 95 |
|- | |- | ||
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
| Line 75: | Line 75: | ||
! Hepatic (CYP3A4) | ! Hepatic (CYP3A4) | ||
! Hepatic (CYP3A4) | ! Hepatic (CYP3A4) | ||
| - | ! Hepatic | + | ! Hepatic (CYP3A4) |
| - | ! Hepatic | + | ! Hepatic (CYP3A4) |
| - | ! Hepatic | + | ! Hepatic (CYP3A4) |
| - | ! | + | ! Hepatic (CYP3A4) |
|} | |} | ||
For references see: [[TYKI_References|References]] | For references see: [[TYKI_References|References]] | ||
Revision as of 18:05, 9 December 2010
| Tyrosine Kinase Inhibitor Pharmacokinetics | ||||||
|---|---|---|---|---|---|---|
| VEGFR & KIT Inhibitors | EGFR Inhibitors | PDGFR Inhibitor | ||||
| Parameter | Sunitinib (Sutent) | Sorafenib (Nexavar) | Erlotinib (Tarceva) | Gefitinib (Iressa) | Lapatinib (Tykerb) | Imatinib (Gleevec) |
| Tmax (hr) | 8 | 8.3 | 2.0 | 5.4 | 4 | 4.6 |
| Cmax (ng/ml) | 24.6 | 460 | 69.6 | 130 | 115 | Imatinib (Gleevec) |
| Bioavailability (%) | Variable | 29-49 | 99 | 59 | Variable | 98 |
| Protein Binding (%) | 95 | 99 | 93 | 90 | 99 | 95 |
| T1/2 (hr) | 83 | 29 | 9.4 | 26.9 | 9.6 | 32 |
| AUC (ng/ml/hr) | 1921 | 11040 | 20577 | 3850 | 1429 | 312 |
| Dosage (mg) | 50 | 50 | 150 | 250 | 100 | 800 |
| Metabolism | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) | Hepatic (CYP3A4) |
For references see: References
